The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading ->
A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading ->
It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading ->